Opinion|Videos|October 21, 2024
Balancing Efficacy Outcomes With Tolerability and Quality of Life in First-Line mRCC Treatment Decisions
Author(s)Rana R. McKay, MD
Panelists discuss how they balance efficacy outcomes like overall survival and progression-free survival against tolerability and quality of life considerations when making decisions about first-line treatment for metastatic renal cell carcinoma patients.
Advertisement
Episodes in this series
- How do efficacy outcomes, such as overall survival and progression-free survival, compare with tolerability and quality of life in your decision-making process for first-line metastatic renal cell carcinoma treatment?
Advertisement
Related to this article
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
3
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
4
Retlirafusp Alfa Improves Overall Survival in Phase 3 Trial of HER2– Gastric Cancer
5